Cell regeneration medicine market forecasts
The cell regeneration medicines market is currently valued at $30.3 billion and is anticipated to reach the valuation of $34.3 billion by the end of 2032 by growing at a CAGR of 14.4%, according to the latest report published by Future Market Insights.
The compound annual growth rate for the forecasted period is significantly higher from the historic CAGR of 12.4%. Furthermore, the market is expected to offer an absolute dollar opportunity of $96.5 billion in the upcoming 10 years.
The therapeutics segment generated the most revenue in the global cell regeneration Medicines Market in 2021. Revenue through this category is expected to grow at a CAGR of 16.5% during the period between 2022 and 2032. This can be attributed to higher adoption of primary cell-based therapies in clinical application and their increased usage in different therapeutic indications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze